Table 1 Clinical description of the study cohort

Age, years

47 (42–50)

48 (36–59)

48 (39–55)

0.72

Gender, number of female patients (%)

2 (13%)

6 (40%)

8 (27%)

0.22

Weight (usual), kg

73 (68–86)

80 (65–93)

78 (65–86)

0.84

Weight at inclusion, kg

94 (77–98)

100 (77–112)

94 (77–104)

0.25

TBSA (%)

75 (54–87)

70 (44–76)

70 (48–84)

0.18

Baux score

117 (103–129)

109 (102–119)

110 (102–125)

0.29

ABSI score

12 (11–13)

11 (10–12)

11 (10–12)

0.06

Inhalation injury, n (%)

9 (60%)

3 (20%)

12 (40%)

0.06

Interval (burn injury-inclusion), h

57 (52–66)

46 (41–58)

54 (42–62)

0.11

Etomidate injection prior to inclusion, n (%)

5 (36%)

12 (80%)

17 (58%)

0.03

Blood transfusions before inclusion, n (%)

4 (27%)

3 (20%)

7 (23%)

1

Diuresis prior to inclusion (L/day)

3.2 (2.0–4.2)

3.5 (2.8–4.3)

3.4 (2.2–4.3)

0.47

Plasma creatinine prior to inclusion, μmol/L

86 (78–128)

88 (59–100)

87 (72–105)

0.28

Plasma protein prior to inclusion, g/L

42 (38–45)

41 (39–45)

42 (38–46)

1

Hemoglobin prior to inclusion, g/L

106 (100–117)

113 (90–132)

110 (94–123)

0.72

White blood cells prior to inclusion, 10⁹/L

5.0 (3.2–7.4)

6.6 (3.5–11.5)

5.3 (3.1–9.6)

0.25

Lymphocytes prior to inclusion, 10⁹/L

0.9 (0.6–1.1)

1.1 (0.8–1.4)

0.9 (0.7–1.3)

0.14

Basal cortisol, µg/dL

15.2 (8.8–21.8)

13.8 (8.4–19.1)

14.5 (8.3–19.9)

0.77

Norepinephrine prior to inclusion, μg/kg/min

0.59 (0.53–0.66)

0.60 (0.51–1.04)

0.60 (0.51–0.78)

0.55

Duration of norepinephrine protocol, h

60 (42–117)

120 (84–141)

102 (56–131)

0.05

Total quantity of norepinephrine over ICU stay, μg/kg

1457 (1132–3705)

1971 (1535–3893)

1771 (1196–4068)

0.27

Septic shock, n (%)

5 (33%)

7 (47%)

12 (40%)

0.71

Number of infections

1 (1–3)

2 (2–3)

2 (1–3)

0.1

Number of skin grafts

4 (1–7)

5 (4–10)

5.00 (1.3–8.5)

0.13

Duration of hospitalization, days

65 (11–77)

67 (51–104)

66 (22–89)

0.11

Deaths before 28 days, n (%)

6 (40%)

2 (13%)

8 (27%)

0.22